IAM
AUTL

Innovis Asset Management’s Autolus Therapeutics AUTL Stock Holding History

Innovis Asset Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$147K Hold
63,179
– – 0.06% 145
2023
Q2 		$150K Sell
63,179
-62,927
-50% -$149K 0.06% 155
2023
Q1 		$232K Buy
+126,106
New +$247K 0.09% 138

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Innovis Asset Management's AUTL Position: Q3 2023 in Review

Innovis Asset Management held its Autolus Therapeutics (AUTL) position steady in Q3 2023 at 63,179 shares worth $147K. The position accounts for 0.06% of the portfolio, ranked #145.

Innovis Asset Management first reported a position in AUTL in Q1 2023 and has held it in 3 quarters since. The position peaked at $232K in Q1 2023. 71 funds tracked by Wall St. Rank hold AUTL as of Q3 2023.

  • Innovis Asset Management held 63,179 shares of Autolus Therapeutics worth $147K as of Q3 2023.
  • Innovis Asset Management left its Autolus Therapeutics share count unchanged in Q3 2023.
  • Autolus Therapeutics made up 0.06% of Innovis Asset Management's portfolio in Q3 2023, its #145 holding.
  • Innovis Asset Management first reported a position in Autolus Therapeutics in Q1 2023 and has held it in 3 quarters since.
  • Innovis Asset Management's Autolus Therapeutics position peaked at $232K in Q1 2023.
  • 71 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2023.

Based on Innovis Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.